Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Results From A Study Using Curcumin Against Pancreatic Cancer

Home/Results From A Study Using Curcumin Against Pancreatic Cancer

Results From A Study Using Curcumin Against Pancreatic Cancer

I understand many of my readers take curcumin as a cancer fighting supplement in an attempt to slow the progression of their multiple myeloma. Here is a lot of information about using curcumin (tumeric) to help stop cancers other than multiple myeloma:

Biological Activity of Curcuminoids from Turmeric Assessed in Patients with Advanced Pancreatic Cancer – April 5, 2010 by CLF
The Journal of the American Botanical CouncilIssue: 81 Page: 23

Pancreatic cancer is almost always lethal, and most patients die within 1 year of diagnosis. The only drugs approved by the Food and Drug Administration that are currently available for treatment are gemcitabine and erlotinib. Both of these drugs elicit responses in only a small percentage of patients (less than 10%), and their effect on survival is measured in weeks. Thus, effective treatments are urgently needed. Many studies have shown that nuclear transcription factor-κB (NF-κB) is activated in patients with pancreatic cancer; therefore, an agent that targets NF-κB may prove effective in the treatment of this disease.

Previous laboratory research has shown that curcuminoids, a group of compounds derived from the traditional herb and spice turmeric (Curcuma longa, Zingiberaceae), suppress NF-κB activation, cell growth associated with apoptosis (programmed cell death), and the growth of human pancreatic cancer xenografts in mice. These curcumoinds are curcumin, desmethoxycurcumin, and bisdesmethoxycurcumin. Phase I human clinical trials of curcuminoids have shown that they are safe at doses up to 8 g/day but that their oral bioavailability may be poor. Thus, this phase II clinical trial was undertaken to determine whether orally administered curcuminoids have biological activity in patients with advanced pancreatic cancer.

Twenty-five patients (13 men, 12 women; aged 43-77) with histologically confirmed pancreatic cancer and a Karnofsky performance score greater than 60 were enrolled in this nonrandomized, open-label, phase II trial, which was conducted at the University of Texas…

…The results of this study indicate that orally administered curcuminoids are tolerated well at doses of 8 g/day for up to 18 months and have “biological activity in some patients with pancreatic cancer.” Although curcumin was poorly absorbed, biological activity (i.e., tumor regression and increase in cytokine concentrations) was evident at steady-state. Because curcumin is hydrophobic (i.e., not water soluble), it cannot be administered intravenously unless encapsulated in a liposome, which would presumably result in higher circulating concentrations of curcumin in the blood. The authors intend to conduct clinical trials in pancreatic cancer patients with the use of liposomal curcuminoids, which they hope will result in more consistent blood concentrations of curcumin and a better pharmacologic effect.

I did not know curcumin wasn’t absorbed well when eaten.  Maybe that is why doses need to be so high to get any results.  You can read the entire article–complete with doses and specific results which led to the researcher’s conclusions–by going to:  Naturally Nutrition, Inc- Turmeric and Curcumin.
Feel good and keep smiling!  Pat